Literature DB >> 33132504

The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring.

Pamela R Kushner1, Davida F Kruger2.   

Abstract

Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient's A1C is adequately controlled. Among the measures captured by CGM, the percentage of time in the target glycemic range, or "time in range" (typically 70-180 mg/dL), has emerged as one of the strongest indicators of good glycemic control. This review examines the shift to using CGM to assess glycemic control and guide diabetes treatment decisions, with a focus on time in range as the key metric of glycemic control.
© 2020 by the American Diabetes Association.

Entities:  

Year:  2020        PMID： 33132504      PMCID： PMC7566931          DOI： 10.2337/cd19-0093

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


  63 in total

Review 1.  Mechanisms of hypoglycemia unawareness and implications in diabetic patients.

Authors:  Iciar Martín-Timón; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2015-07-10

2.  Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline.

Authors:  Anne L Peters; Andrew J Ahmann; Tadej Battelino; Alison Evert; Irl B Hirsch; M Hassan Murad; William E Winter; Howard Wolpert
Journal:  J Clin Endocrinol Metab       Date:  2016-09-02       Impact factor: 5.958

3.  The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.

Authors:  Helena W Rodbard; Anne L Peters; April Slee; Anjun Cao; Shana B Traina; Maria Alba
Journal:  Diabetes Care       Date:  2016-11-29       Impact factor: 19.112

Review 4.  Utility of different glycemic control metrics for optimizing management of diabetes.

Authors:  Klaus-Dieter Kohnert; Peter Heinke; Lutz Vogt; Eckhard Salzsieder
Journal:  World J Diabetes       Date:  2015-02-15

Review 5.  User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

Authors:  Charles F Shaefer; Pamela Kushner; Richard Aguilar
Journal:  Postgrad Med       Date:  2015-09-15       Impact factor: 3.840

Review 6.  Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.

Authors:  L van Bloemendaal; J S Ten Kulve; S E la Fleur; R G Ijzerman; M Diamant
Journal:  J Endocrinol       Date:  2014-03-07       Impact factor: 4.286

7.  Lag Time Remains with Newer Real-Time Continuous Glucose Monitoring Technology During Aerobic Exercise in Adults Living with Type 1 Diabetes.

Authors:  Dessi P Zaharieva; Kamuran Turksoy; Sarah M McGaugh; Rubin Pooni; Todd Vienneau; Trang Ly; Michael C Riddell
Journal:  Diabetes Technol Ther       Date:  2019-05-06       Impact factor: 6.118

8.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetologia       Date:  2018-12       Impact factor: 10.122

Review 9.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Authors:  Tadej Battelino; Thomas Danne; Richard M Bergenstal; Stephanie A Amiel; Roy Beck; Torben Biester; Emanuele Bosi; Bruce A Buckingham; William T Cefalu; Kelly L Close; Claudio Cobelli; Eyal Dassau; J Hans DeVries; Kim C Donaghue; Klemen Dovc; Francis J Doyle; Satish Garg; George Grunberger; Simon Heller; Lutz Heinemann; Irl B Hirsch; Roman Hovorka; Weiping Jia; Olga Kordonouri; Boris Kovatchev; Aaron Kowalski; Lori Laffel; Brian Levine; Alexander Mayorov; Chantal Mathieu; Helen R Murphy; Revital Nimri; Kirsten Nørgaard; Christopher G Parkin; Eric Renard; David Rodbard; Banshi Saboo; Desmond Schatz; Keaton Stoner; Tatsuiko Urakami; Stuart A Weinzimer; Moshe Phillip
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

10.  Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.

Authors:  Juan P Frías; Samer Nakhle; James A Ruggles; Sergey Zhuplatov; Eric Klein; Rong Zhou; Poul Strange
Journal:  Diabetes Obes Metab       Date:  2016-09-21       Impact factor: 6.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.